Oğuz KÖKSEL, Erhan AYAN, Ali ÖZDÜLGER, Murat Bayram KAPLAN

Altı yıldır hayatta olan bir peritoneal, plevral mezotelyoma olgusu

Malign mezotelyoma plevra, perikard ve peritonu döşeyen serozal zarın kötü prognozlu ve fatal seyirli primer malign tümörüdür. Beklenen ortalama yaşam süresi, tedavi uygulanmadığında 4-12 ay arasındadır. Çoğunlukla plevral yerleşimli olan, klinik davranışı ve biyolojisi henüz tam olarak anlaşılamayan malign mezotelyoma, epidemiyolojik çalışmalar, tanı, evreleme yöntemleri ve tedavi modaliteleri ile araştırmalara konu olmaktadır. Bu yazıda birinci basamak kemoterapi dışında küratif bir tedavi almaksızın altı yıldır hayatta olan plevra ve periton yerleşimli bir malign mezotelyoma olgusunun etyolojik faktörleri değerlendirildi ve literatür eşliğinde sunuldu.

A peritoneal, pleural mesothelioma case who has survived for six years

Malignant mesothelioma, which has a poor prognosis and fatal course, is a primary malignant tumor of serosal membrane of pleura, pericardium and peritoneum. Expected mean survival time is 4-12 months when no treatment is administered. Malignant mesothelioma is commonly located in the pleural space and its clinical behaviour and biology has not been understood exactly yet. Epidemiological studies, diagnosis, grading methods and treatment modalities concerning this disease have been the subject of investigations. We are presenting a pleural and peritoneal malignant mesothelioma case who has survived for six years without any other curative treatment except for the first line chemotherapy and we evaluate etiological factors along with the information in the literature.

PDF

___

1) Flores RM, Rusch VW. Diffuse malignant mesothelioma. In: Shields T, editor. General thoracic surgery. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 901-21.
2) De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 2002;84:455-9.
3) Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001;19:346-50.
4) Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, et al. Prognostic factors in mesothelioma. Lung Cancer 2005;49(Suppl 1):S49-52.
5) Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-5.
6) Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005;10:266-83.
7) Wong CF, Fung SL, Yew WW, Fu KH. A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment. Respiration 2002;69:166-8.
8) Uzunlar AK, Yaldız M, Kılınç N, Kırbaş G, Arslan A. Plevra malign mezotelyomalarında prognostik faktörler. Türkiye Ekopatoloji Dergisi 2000;6:175-9.